AMEX · Drug Manufacturers - Specialty & Generic
cbdMD, Inc. (YCBD) Stock
$0.39
-1.24%
AMEX: YCBD
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
cbdMD's Oasis Brand Partners with Mexcor to Launch Into South Carolina
PR Newswire · Jul 14, 2026
cbdMD's Bluebird Botanicals Announces Official Partnership With Denver Audubon to Support Bird Conservation
PR Newswire · Jul 9, 2026
cbdMD Sets a New Safety Standard for Broad Spectrum CBD With Self-Affirmed GRAS Determination
PR Newswire · Jul 7, 2026
Oasis Launches Hemp-Derived Mixer
PR Newswire · Jul 1, 2026
cbdMD Welcomes White House Call for Fair Treatment of Hemp-Derived Products
PR Newswire · Jun 25, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held10.68%
Institutions Held8.96%
Institutions Float Held10.03%
Peer Comparison
About cbdMD, Inc.
cbdMD, Inc. is led by CEO T. Ronan Kennedy, publicly traded since 2017.
cbdMD, Inc. (YCBD) stock trades at $0.39 with a market capitalization of $4.09M. The stock is valued at a price-to-earnings (P/E) ratio of -1.49, price-to-book of 0.59, price-to-sales of 0.23. Over the past 52 weeks the stock has ranged between $0.39 and $2.56, and currently trades 84.8% below its 52-week high.
On profitability, cbdMD, Inc. generates a return on equity (ROE) of -34.25%, return on capital employed of -28.84%, an operating margin of -10.53%, a net profit margin of -13.80%.